Description
Thehistochemicalantibodyfor5-HT1Areceptorisgeneratedinarabbitagainstsyntheticpeptidesequencecorrespondingtoaminoacids294-312oftherat5-HT1Areceptor.Theantiserumisprovidedas100µlofaffinitypurifiedserumcontaining1%BSA.Controls:TheImmunoStar5-HT1Areceptorantiserumwasqualitycontroltestedusingstandardimmunohistochemicalmethods.
Theantiserumdemonstratesstronglypositivelabelingofratcortex,arcuateandhippocampususingindirectimmunofluorescentandbiotin/avidin-HRPtechniques.Recommendedprimarydilutionsare1/200-1/300inPBS-Bn/Av-HRPdetection.Intensificationmethodssuchasnickelwillapproximatelydoublethedilutionfactorasrecommended.
TheantibodywascharacterizedbyimmunohistochemistryandWesternblot.Westernblotshowedasinglebandofapproximately45kDusingadilutionof1/100.Thewesterninformationisincludedasspecificityinformation.Preincubationoftheantibodywithanexcessofthesyntheticpeptideblockedstaining.ImmunohistochemicalstainingofratbraincorrelateswellwithNorthernanalysis,insituhybridizationandreceptorautorADIography.
BlastPdatabasesequencehomologysearchesconfirmedthatthissequenceisuniquetorat,mouseandhuman5-HT1Areceptors.
PhotoDescription:IHCimageofneuronsstainingforthe5-HT1Areceptorintheratcortex(above)and5HT1Areceptorstainingofastrocytesintherathippocampus(below).Thetissuewasfixedwith4%formaldehyde/0.05%glutaraldehydein0.1Mphosphatebuffer,beforebeingremovedandpreparedforvibratomesectioning.FloatingsectionswereincubatedatRTin10%goatseruminPBS,beforestandardIHCprocedure.Primaryantibodywasincubatedat1:500for48hours,goatanti-rabbitsecondarywassubsequentlyaddedfor1hourafterwashingwithPBS.Lightmicroscopystainingwasachievedwithstandardbiotin-streptavidin/HRPprocedureandDABchromogen.
Host:Rabbit
Quantity/Volume:100µL
State:Liquid
AvailABIlity: InStock
ReactsWith:GuineaPig,Human,Monkey,Mouse,Rat
AlternateNames: 5-hydroxytryptaminereceptor1A;ADRB2RL1;ADRBRL1;RAT5HT1A,5-hydroxytryptamine(SEROtonin)receptor1A,Gprotein-coupled,anti-5-HT1A
RRID:AB_572210
Immunogen:Rat5-HT1Areceptor(294-312)
GeneSymbol/ID,Accession#: Htr1a,24473
阿尔茨海默氏症协会称，阿尔茨海默氏症的研究抗体在帮助科学家找到解决这种疾病和其他痴呆症的方法方面发挥着重要作用，这些疾病和痴呆症影响了全世界4700万人和530万美国人，到2050年，这一数字有望增加两倍。随着婴儿潮一代的年龄增长，预计将有2800万人患上这种疾病，其费用将升至美国医疗保险总支出的近四分之一。
自从Aloysius Alzheimer博士于1906年首次描述这种疾病以来，科学家们在了解这种疾病如何影响大脑方面取得了显着进步。十多年后，理解和治疗的突破为阿尔茨海默氏病患者带来了希望。
这些ImmunoStar抗体已在阿尔茨海默氏症的研究中得到证明。用关键字“阿尔茨海默氏病” 搜索我们出版物的数据库，以查找数百种引用这些抗体的出版物。有关神经科学家的意见，请参阅我们的客户推荐书，以赞扬他们从ImmunoStar获得的结果和服务。我们的抗体稳定，高滴度，并且批次间一致，可确保成功染色并获得极佳的价值。
暂无问答
本网站将在规定时间内给予删除等相关处理。
